Ibrutinib Is Associated With Increased Cardiovascular Events and Major Bleeding in Older CLL Patients.

ABSTRACT:

Background

Early ibrutinib trials showed an association between ibrutinib use and risk of bleeding and atrial fibrillation (AF) in younger chronic lymphocytic leukemia (CLL) patients. Little is known about these adverse events in older CLL patients and whether increased AF rates are associated with increased stroke risk.

Objectives

To compare the incidence of stroke, AF, myocardial infarction, and bleeding in CLL patients treated with ibrutinib with those who were treated without ibrutinib in a linked SEER-Medicare database.

Methods

The incidence rate of each adverse event for treated and untreated patients was calculated. Among those treated, inverse probability weighted Cox proportional hazards regression models were used to calculate HRs and 95% CIs for the associa

SUBMITTER: Diamond A 

PROVIDER: S-EPMC10152196 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature